Ultimovacs Asa Stock Fundamentals
| ULTI Stock | NOK 2.00 0.01 0.50% |
Ultimovacs ASA fundamentals help investors to digest information that contributes to Ultimovacs ASA's financial success or failures. It also enables traders to predict the movement of Ultimovacs Stock. The fundamental analysis module provides a way to measure Ultimovacs ASA's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ultimovacs ASA stock.
Ultimovacs |
Ultimovacs ASA Company Return On Equity Analysis
Ultimovacs ASA's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Ultimovacs ASA Return On Equity | -0.33 |
Most of Ultimovacs ASA's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ultimovacs ASA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Ultimovacs ASA has a Return On Equity of -0.3318. This is 98.62% lower than that of the Healthcare sector and 99.09% lower than that of the Biotechnology industry. The return on equity for all Norway stocks is 7.03% higher than that of the company.
Ultimovacs ASA Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Ultimovacs ASA's current stock value. Our valuation model uses many indicators to compare Ultimovacs ASA value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Ultimovacs ASA competition to find correlations between indicators driving Ultimovacs ASA's intrinsic value. More Info.Ultimovacs ASA is rated first in return on equity category among its peers. It is rated first in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Ultimovacs ASA's earnings, one of the primary drivers of an investment's value.Ultimovacs Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ultimovacs ASA's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Ultimovacs ASA could also be used in its relative valuation, which is a method of valuing Ultimovacs ASA by comparing valuation metrics of similar companies.Ultimovacs ASA is currently under evaluation in return on equity category among its peers.
Ultimovacs Fundamentals
| Return On Equity | -0.33 | |||
| Return On Asset | -0.2 | |||
| Current Valuation | 3.35 B | |||
| Shares Outstanding | 34.4 M | |||
| Shares Owned By Insiders | 48.41 % | |||
| Shares Owned By Institutions | 24.83 % | |||
| Price To Book | 7.44 X | |||
| EBITDA | (161.69 M) | |||
| Net Income | (164.72 M) | |||
| Cash And Equivalents | 1.85 M | |||
| Cash Per Share | 11.95 X | |||
| Total Debt | 457 K | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 12.47 X | |||
| Book Value Per Share | 14.97 X | |||
| Cash Flow From Operations | (125.83 M) | |||
| Earnings Per Share | (5.09) X | |||
| Target Price | 165.0 | |||
| Number Of Employees | 23 | |||
| Beta | 1.42 | |||
| Market Capitalization | 4.11 B | |||
| Total Asset | 655.54 M | |||
| Net Asset | 655.54 M |
About Ultimovacs ASA Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ultimovacs ASA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ultimovacs ASA using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ultimovacs ASA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for various cancers. The company was incorporated in 2011 and is headquartered in Oslo, Norway. ULTIMOVACS ASA is traded on Oslo Stock Exchange in Norway.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Ultimovacs Stock
Ultimovacs ASA financial ratios help investors to determine whether Ultimovacs Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ultimovacs with respect to the benefits of owning Ultimovacs ASA security.